Aged Aged 80 and over Chemoradiotherapy/*mortality/*statistics & numerical data Combined Modality Therapy Cystectomy/*mortality/*statistics & numerical data Disease-Free Survival Female Humans Male Middle Aged Neoplasm Invasiveness Postoperative Complications/mortality/prevention & control Prevalence Radiation Injuries/mortality/prevention & control Risk Factors Survival Rate Treatment Outcome Urinary Bladder Neoplasms/*mortality/*therapy

Cystectomy/*methods Humans Length of Stay Operative Time Postoperative Complications Robotic Surgical Procedures/*methods Treatment Outcome Urinary Bladder Neoplasms/*surgery bladder cancer cystectomy robotics

Adjuvants Immunologic/*administration & dosage Administration Intravesical Antineoplastic Agents/therapeutic use BCG Vaccine/*administration & dosage Humans Instillation Drug Randomized Controlled Trials as Topic Urinary Bladder Neoplasms/pathology/*therapy Bacillus Calmette-Guerin Maintenance therapy Non-muscle-invasive bladder cancer Progression Recurrence

Cardiovascular Diseases/*etiology Cohort Studies Humans Hypoglycemic Agents/*adverse effects/pharmacology Non-alcoholic Fatty Liver Disease/*etiology/pathology Pioglitazone Prevalence Risk Thiazolidinediones/*adverse effects/pharmacology Urinary Bladder Neoplasms/epidemiology/*etiology/pathology Bladder cancer Cardiovascular disease Non-alcoholic steatohepatitis

Asian People/genetics Biomarkers Tumor/*blood/urine Cystoscopy/adverse effects Humans MicroRNAs/*blood Neoplasm Staging Nuclear Proteins/urine Odds Ratio ROC Curve Regression Analysis Sensitivity and Specificity Urinalysis/methods Urinary Bladder Neoplasms/*blood/diagnosis/*genetics/urine Bladder cancer Diagnosis Meta-analysis miRNA authors declare that they have no competing interests. PUBLISHER’S NOTE: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Cystectomy/*methods Female Humans Organ Sparing Treatments/*methods Postoperative Complications Sexual Dysfunction Physiological/*prevention & control Treatment Outcome Urinary Bladder/*pathology Urinary Bladder Neoplasms/physiopathology/*surgery Urinary Diversion/*methods Urinary Incontinence/*prevention & control #BladderCancer #blcsm radical cystectomy sexual function urinary bladder neoplasms urinary incontinence

Cystectomy/*adverse effects Diurnal Enuresis/etiology Female Humans Nocturnal Enuresis/etiology *Quality of Life Sexual Dysfunction Physiological/*etiology/physiopathology Urinary Bladder Neoplasms/*surgery Urinary Diversion/adverse effects Urinary Incontinence/*etiology Cystectomy Functional outcomes Gender disparities Outcomes assessment Urinary bladder neoplasms

*Adaptation Psychological Humans Quality of Life Survivors/*psychology Urinary Bladder Neoplasms/mortality/pathology/*psychology Bladder cancer Cystectomy Diagnosis Patients’ experience Treatment FUNDING: This work was funded by Yorkshire Cancer Research (grant number S388).

*Biomarkers Tumor Disease Progression Gene Expression Humans Matrix Metalloproteinases/*genetics/metabolism Prognosis Publication Bias Survival Analysis Urinary Bladder Neoplasms/*genetics/metabolism/*mortality/pathology bladder cancer matrix metalloproteinases meta-analysis

Adjuvants Immunologic/*administration & dosage/adverse effects Administration Intravesical Antineoplastic Agents/*administration & dosage/adverse effects BCG Vaccine Carcinoma in Situ/mortality/pathology/*therapy Combined Modality Therapy/adverse effects/methods Disease Progression Drug Administration Schedule Humans Interferon-alpha/*administration & dosage/adverse effects Neoplasm Recurrence Local Randomized Controlled Trials as Topic Time Factors Urinary Bladder Neoplasms/mortality/pathology/*therapy Withholding Treatment/statistics & numerical data

Administration Intravesical Antineoplastic Agents/*administration & dosage/adverse effects Asymptomatic Diseases BCG Vaccine/*administration & dosage/adverse effects Bacteriuria/*complications/diagnosis Humans Immunotherapy/adverse effects/*methods Neoplasm Invasiveness Risk Assessment Treatment Outcome Urinary Bladder Neoplasms/complications/*drug therapy/immunology/pathology Bacillus Calmette-Guerin Bacteriuria Bladder cancer Intravesical instillation

Adult Aged Aged 80 and over Humans Magnetic Resonance Imaging/standards Middle Aged Muscle Neoplasms/*diagnosis Neoplasm Invasiveness Sensitivity and Specificity Urinary Bladder Neoplasms/*diagnosis Bladder cancer Local staging Magnetic resonance imaging Meta-analysis Muscle-invasive bladder cancer Systematic review

Arylamine N-Acetyltransferase/*genetics Genetic Predisposition to Disease Humans Isoenzymes/genetics Polymorphism Genetic Urinary Bladder Neoplasms/*genetics

Arylsulfotransferase/*genetics Case-Control Studies Genetic Association Studies Genetic Predisposition to Disease Genotype Humans NAD(P)H Dehydrogenase (Quinone)/*genetics Odds Ratio *Polymorphism Genetic Risk Factors Smoking/*adverse effects Urinary Bladder Neoplasms/enzymology/*genetics Nqo1 Sult1a1 meta-analysis polymorphisms smoking urinary bladder neoplasms

Age Factors Cystoscopy/*methods Cytodiagnosis Hematuria/*complications/*diagnosis Humans Predictive Value of Tests Sex Factors Smoking Time Factors Urinary Bladder Neoplasms/*complications/diagnosis/urine bladder cancer diagnosis haematuria timeliness urinary bladder neoplasm

Administration Intravesical Antibiotics Antineoplastic/*administration & dosage BCG Vaccine/administration & dosage Carcinoma in Situ/*drug therapy/mortality/pathology Carcinoma Transitional Cell/*drug therapy/mortality/pathology Disease Progression Electrochemotherapy/adverse effects/*methods Humans Mitomycin/*administration & dosage Neoplasm Recurrence Local Randomized Controlled Trials as Topic Time Factors Urinary Bladder Neoplasms/*drug therapy/mortality/pathology

Biomarkers Tumor/genetics/urine Humans RNA/urine Sensitivity and Specificity Software Survivin/genetics/*urine Urinary Bladder Neoplasms/*diagnosis/*urine Bladder cancer Diagnosis Meta-analysis Survivin

Administration Intravesical BCG Vaccine/therapeutic use Disease Progression Female Humans *Ki-67 Antigen Male *Neoplasm Invasiveness Prognosis Prospective Studies *Urinary Bladder Neoplasms/diagnosis/drug therapy/pathology Ki67 meta-analysis non-muscular-invasive bladder cancer

Anemia/*complications Cystectomy/*methods Female Humans Male Preoperative Period Proportional Hazards Models Survival Analysis Treatment Outcome Urinary Bladder Neoplasms/*surgery Anemia Bladder cancer Hemoglobin Mortality Recurrence

Administration Intravesical BCG Vaccine/administration & dosage/*therapeutic use Chemotherapy Adjuvant Dose-Response Relationship Drug Drug Administration Schedule Humans Neoplasm Recurrence Local Prospective Studies Randomized Controlled Trials as Topic Urinary Bladder Neoplasms/*drug therapy/mortality/surgery